HARMONY BIOSCIENCES HOLDINGS, INC. Repayments of Long-Term Debt
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Repayments of Long-Term Debt of $10.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for the quarter ending 2026-06-30 was $5.00M, a 33.33% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for the quarter ending 2026-03-31 was $5.00M, a 33.33% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for the quarter ending 2025-12-31 was $5.00M, a 33.33% increase year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for the quarter ending 2025-09-30 was $3.75M, a 0.00% change year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for fiscal 2025 was $16.25M, a 8.33% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for fiscal 2024 was $15.00M, a 215.79% increase from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for fiscal 2023 was $4.75M, a 137.50% increase from fiscal 2022.
- HARMONY BIOSCIENCES HOLDINGS, INC. repayments of long-term debt for fiscal 2022 was $2.00M, a 300.00% increase from fiscal 2021.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $10.00M 10-Q · filed 2026-08-04 | $15.00M derived: sum of 3 quarters · filed 2026-08-04 | $18.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-07 | $10.00M derived: sum of 2 quarters · filed 2026-05-07 | $13.75M derived: sum of 3 quarters · filed 2026-05-07 | $17.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.75M derived: sum of 2 quarters · filed 2026-02-24 | $12.50M derived: sum of 3 quarters · filed 2026-08-04 | $16.25M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.50M derived: sum of 2 quarters · filed 2026-08-04 | $11.25M 10-Q · filed 2025-11-04 | $15.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $7.50M 10-Q · filed 2026-08-04 | $11.25M derived: sum of 3 quarters · filed 2026-08-04 | $15.00M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.75M 10-Q · filed 2026-05-07 | $7.50M derived: sum of 2 quarters · filed 2026-05-07 | $11.25M derived: sum of 3 quarters · filed 2026-05-07 | $15.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.50M derived: sum of 2 quarters · filed 2026-02-24 | $11.25M derived: sum of 3 quarters · filed 2026-02-24 | $15.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $7.50M derived: sum of 2 quarters · filed 2025-11-04 | $11.25M 10-Q · filed 2025-11-04 | $15.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.50M 10-Q · filed 2025-08-05 | $11.25M derived: sum of 3 quarters · filed 2026-02-24 | $11.25M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $3.75M 10-Q · filed 2025-05-06 | $7.50M derived: sum of 2 quarters · filed 2026-02-24 | $7.50M derived: sum of 3 quarters · filed 2026-02-24 | $8.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.75M derived: sum of 2 quarters · filed 2026-02-24 | $4.25M derived: sum of 3 quarters · filed 2026-02-24 | $4.75M 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $500.00K derived: sum of 2 quarters · filed 2024-10-29 | $1.00M 10-Q · filed 2024-10-29 | $1.50M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.00M 10-Q · filed 2024-08-06 | $1.50M derived: sum of 3 quarters · filed 2025-02-25 | $2.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $500.00K 10-Q · filed 2024-04-30 | $1.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.50M derived: sum of 3 quarters · filed 2025-02-25 | $2.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.00M derived: sum of 2 quarters · filed 2025-02-25 | $1.50M derived: sum of 3 quarters · filed 2025-02-25 | $2.00M 10-K · filed 2025-02-25 |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $1.00M derived: sum of 2 quarters · filed 2023-10-31 | $1.50M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $1.00M 10-Q · filed 2023-08-01 | ||
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $500.00K 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |